BIFIDO Co., Ltd.
Financials
Valuation Metrics
BIFIDO Co., Ltd.'s Market Cap is ₩210B. At end of 2025 it was ₩251B. Ranked #2297 of 2,436 in KR market (top 94%), #1520 of 1,649 on KOSDAQ (top 92%), #52 of 57 in Household & Personal Products (top 91%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 21.02B KRW | KR#2,297/2,436 Sec#52/57 |
| Revenue | 17.23B KRW | KR#2,174/2,436 Sec#49/57 |
| Net Income | -1.89B KRW | KR—/2,436 Sec—/57 |
| Total Assets | 57.01B KRW | KR#2,122/2,436 Sec#48/57 |
| Net Assets | 44.44B KRW | KR#1,958/2,436 Sec#44/57 |
| Employees | 101 | KR#1,615/2,436 Sec#34/57 |
| Value | ||
| P/B | 0.47x | KR#733/2,436 Sec#15/57 |
| P/S | 1.22x | KR#1,533/2,436 Sec#41/57 |
| EV/EBITDA | 35.13x | KR#1,240/2,436 Sec#31/57 |
| FCF Yield | -15.43% | KR—/2,436 Sec—/57 |
| Profitability | ||
| ROE | -4.24% | KR#1,721/2,436 Sec#40/57 |
| ROA | -3.31% | KR#1,795/2,436 Sec#42/57 |
| Op. Margin | 4.22% | KR#1,023/2,436 Sec#29/57 |
| Revenue Growth | -49.57% | KR#2,278/2,436 Sec#55/57 |
| Earnings Growth | -909.11% | KR#1,686/2,436 Sec#38/57 |
| Financial Health | ||
| Debt Ratio | 128.28% | KR#815/2,436 Sec#26/57 |
| Total Debt | 10.00B KRW | KR#1,624/2,436 Sec#37/57 |
| FCF | -3.24B KRW | KR#1,408/2,436 Sec#39/57 |
| Cash | 5.48B KRW | KR#1,956/2,436 Sec#45/57 |
| Current Ratio | 2.88x | KR#647/2,436 Sec#19/57 |
| Net Debt/EBITDA | 6.21x | KR#1,155/2,436 Sec#32/57 |
| Performance | ||
| 1Y Return | -29.49% | KR#1,446/2,436 Sec#25/57 |
| 1M Return | 6.20% | KR#528/2,436 Sec#19/57 |
| From 52W High | -41.46% | KR#842/2,436 Sec#26/57 |
| 1Y MDD | -48.90% | KR#884/2,436 Sec#24/57 |
| Trading | ||
| Volume | 21,001 shares | KR#2,076/2,436 Sec#47/57 |
| Foreign Own. | 0.99% | KR—/2,436 Sec—/57 |
| Per Share | ||
| EPS | 280 KRW | KR#1,120/2,436 Sec#26/57 |
| BPS | 5,943 KRW | KR#1,311/2,436 Sec#28/57 |
Company Info
Bifido, established in 1999 and listed on KOSDAQ in 2018, manufactures Bifidobacterium-based probiotics discovered in Korean infant intestines. It operates its own brand, Bifidolab, and provides domestic and international ODM services, possessing a proprietary patented strain, the sixth in the world to receive NDI and GRAS certifications from the US FDA. Through the development of MAP-based functional probiotics and eLBP microbiome therapeutics, Bifido is building a competitive pipeline targeting immune, cancer, and infectious diseases.